ArticleHeliyon2019
EGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriers.
Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- EGCG Derivatives Alleviate Diquat-Induced Liver and Gut Damage in Mice by Activating an Antioxidant Pathway and Enhancing Barrier Function.Animals : an open access journal from MDPI · 2026Article
- Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential.Frontiers in pharmacology · 2026Review
- Advancement in nanocarrier-mediated delivery of herbal bioactives: from bench to beside.Natural products and bioprospecting · 2025Review
- Anticancer Molecular Mechanisms of Epigallocatechin Gallate: An Updated Review on Clinical Trials.Food science & nutrition · 2025Review
- Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment.Pharmaceutical biology · 2024Review
- Article
- Whey Protein Sodium-Caseinate as a Deliverable Vector for EGCG: In Vitro Optimization of Its Bioaccessibility, Bioavailability, and Bioactivity Mode of Actions.Molecules (Basel, Switzerland) · 2024Article
- Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy.Molecules (Basel, Switzerland) · 2024Review
- Surface Functionalized Lipid Nanoparticles in Promoting Therapeutic Outcomes: An Insight View of the Dynamic Drug Delivery System.Current drug targets · 2024Review
- Exploiting Nanotechnology for Drug Delivery: Advancing the Anti-Cancer Effects of Autophagy-Modulating Compounds in Traditional Chinese Medicine.International journal of nanomedicine · 2024Review
- The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review.Current medicinal chemistry · 2024Review
- Folic acid-modified reverse micelle-lipid nanocapsules overcome intestinal barriers and improve the oral delivery of peptides.Drug delivery · 2023Article
- Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals.International journal of molecular sciences · 2023Review
- Flavonoids in the Spotlight: Bridging the Gap between Physicochemical Properties and Formulation Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- NovelPharmaceuticals (Basel, Switzerland) · 2022Article
- Aqueous core epigallocatechin gallate PLGA nanocapsules: characterization, antibacterial activity against uropathogens, andDrug delivery · 2022Article
- Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines.ACS omega · 2022Article
- Oral Cell-Targeted Delivery Systems Constructed of Edible Materials: Advantages and Challenges.Molecules (Basel, Switzerland) · 2022Review
- Antibiofilm Combinatory Strategy: Moxifloxacin-Loaded Nanosystems and EncapsulatedPharmaceutics · 2022Article
- Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work aimed to develop folic acid-functionalized nanostructured lipid carriers (NLC) loading epigallocatechin-3-gallate (EGCG) to increase its oral bioavailability. An active targeting strategy was used and these nanoparticles (NPs) were fully characterized. The NP's effect on Caco-2 cell viability was evaluated and the apparent permeability (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.